Program
JSKN033
A development code. Also written as “JSKN033 Injection”.
Its studies are mostly in Uterine Cervical Neoplasms · Carcinoma, Non-Small-Cell Lung, led by Alphamab Oncology.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Alphamab Oncology | 54 open or running | phase 3since Aug 25, 2026 | Dec 22, 2023 | Dec 31, 2026phase 2 · NCT06770881 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Dec 22, 2023First study: phase 2 study in Advanced Solid TumorFirst studyNCT06226766 · 11 enrolled · Australia
- Dec 27, 2024Phase 2 study in Advanced Malignant TumorsNCT06770881 · 430 planned
- Dec 2, 2025Phase 2 study in Carcinoma, Non-Small-Cell LungNCT07283198 · 160 planned
- Mar 10, 2026Phase 2 study in Uterine Cervical NeoplasmsNCT07497074 · 78 planned · China
- Aug 25, 2026Phase 3 study in RecurrencePhase 3 reachedNCT07797153 · 368 planned · China
Ahead
- Dec 31, 2026Primary completion: phase 2 study in Advanced Malignant TumorsNCT06770881
- Aug 30, 2027Primary completion: phase 2 study in Carcinoma, Non-Small-Cell LungNCT07283198
- Oct 2027Primary completion: phase 2 study in Uterine Cervical NeoplasmsNCT07497074
- Dec 2028Primary completion: phase 3 study in RecurrenceNCT07797153
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 5 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07797153Recurrence · China | 3 | Not yet recruiting | Dec 2028 | 368 |
| NCT07497074Uterine Cervical Neoplasms · China | 2 | Not yet recruiting | Oct 2027 | 78 |
| NCT07283198Carcinoma, Non-Small-Cell Lung | 2 | Not yet recruiting | Aug 30, 2027 | 160 |
| NCT06770881Advanced Malignant Tumors | 2 | Not yet recruiting | Dec 31, 2026 | 430 |
| NCT06226766Advanced Solid Tumor · Australia | 2 | Terminated | Jul 31, 2025 | 11 |
How it is read
Names in the registry
- “JSKN033”, 3 entries
- “JSKN033 Injection”, 2 entries
Codes read as this program: JSKN033.
Conditions, from the studies’ own filings
- Uterine Cervical Neoplasms, 2 studies
- Carcinoma, Non-Small-Cell Lung, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.